A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Clinical trial NCT02807454 · TERMINATED
Trial details
- NCT number
- NCT02807454
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-07
- Primary completion
- 2022-01-03
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.